Panion presented at InvestorDagen in Århus, Denmark, the 12.th of June 2018
The progress and plans for Panion's development of the gene therapy treatment for dogs with epilepsy, and for Panion's business idea and vision, was presented by Anja Holm, CEO of Panion, at the InvestorDagen event in Århus, Denmark on the 12.th of June.
A webcast of the presentation can be found here (in Danish): https://getvisualtv.net/stream/?daf-investordagen-aarhus-120618#panion-animal-health
"The day was well-attended with approximately 500 visitors for the entire event, and I experienced good interest for Panion's unique product development and for the presentation. Most people own dogs or cats and can easily understand the willingness to pay for treatments when the pets are seriously ill", says Anja Holm. "It was very satisfying to talk with both existing shareholders and new, interested persons during the day. AktieTorget will enter the Danish market later this year, so we find it very relevant to reach out to interested investors in Denmark."
InvestorDagen, Dansk Aktionærforening, @Shareholders.dk
Anja E. H. Holm, CEO
+ 45-22 94 66 00
Bolaget ska utveckla och kommersialisera genterapi för behandling av epilepsiliknande tillstånd hos hundar och andra djur, samt utveckla och kommersialisera andra veterinärmedicinska produkter och nya behandlingsformer som kan ge sjuka djur bättre livskvalitet.
Panion will develop and commercialize a gene therapy treatment for dogs with drug refractory epilepsy, and other new animal health products and treatments that improve the quality of life for animals suffering from chronic diseases.
The rights issue in Panion Animal Health AB has been registered by the Swedish Companies Registration Office
The rights issue which was decided by the Board of Panion Animal Health AB, with the authorization of the Annual General Meeting of 29 May 2018, has now been registered by the Swedish Companies Registration Office. Shares and share capital after the registration by the Swedish Companies Registration Office amount to SEK 1,137,110.723254 divided into 24,399,487 shares.
Panion Animal Health AB develops a novel gene therapy treatment for dogs with epilepsy. The first clinical trial will be conducted at Long Island Veterinary Specialists, Ophthalmology, Surgery, Internal Medicine, Emergency, PLLC ("LIVS") in New York, USA. It is a pilot study to evaluate the efficacy of the treatment in patient dogs with idiopathic epilepsy. It is the first time that the gene therapy treatment is made available for client-owned family dogs.
Panion Animal Health AB invites all interested persons to an investor meeting at Mangolds offices, Engelbrektsplan 2, Stockholm on Friday the 14th of December 2018 from 12 - 13.
Panion Animal Health AB
Marknadsplats: Spotlight Stock Market
Year End Report 2017
2019-02-22 Delårsrapport Q4 2018